✦ LIBER ✦

P573 Changes in resource utilisation in patients with Crohn's disease treated with adalimumab in routine clinical practice

✍ Scribed by Saro, C.; Ceballos, D.; Muñoz, F.; De la Coba, C.; Aguilar, M.D.; Lazaro, P.

Book ID: 121959272
Publisher: Oxford University Press
Year: 2013
Tongue: English
Weight: 52 KB
Volume: 7
Category: Article
ISSN: 1873-9946
DOI: 10.1016/S1873-9946(13)60594-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P563 Clinical response and quality of li

P563 Clinical response and quality of life in patients with Crohn's disease treated with adalimumab in routine clinical practice

✍ Ceballos, D.; Muñoz, F.; Saro, C.; De la Coba, C.; Aguilar, M.D.; Lazaro, P. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 54 KB

P564 Clinical response, quality of life

P564 Clinical response, quality of life and work activity in patients with Crohn's disease treated with adalimumab in routine clinical practice

✍ Saro, C.; Ceballos, D.; Muñoz, F.; De la Coba, C.; Aguilar, M.D.; Lazaro, P. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 65 KB

Resource use in patients with Crohn’s di

Resource use in patients with Crohn’s disease treated with infliximab

✍ C. SARO; C. DE LA COBA; M. Á. CASADO; J. M. MORALES; B. OTERO 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

Pneumocystosis in a patient with Crohn's

Pneumocystosis in a patient with Crohn's disease treated with combination therapy with adalimumab

✍ Ana L. Desales; Jorge Mendez-Navarro; Luis J. Méndez-Tovar; Nayeli X. Ortiz-Olve 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 504 KB

Acute coronary syndrome in a Crohn's dis

Acute coronary syndrome in a Crohn's disease patient treated with adalimumab

✍ Petitpain, Nadine; Bornert-Keller, Nathalie; Peyrin-Biroulet, Laurent 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 141 KB

Adalimumab safety in global clinical tri

Adalimumab safety in global clinical trials of patients with Crohn's disease

✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr